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INTRODUCTION {#ner12908-sec-0008}
============

Painful diabetic peripheral neuropathy (PDPN) is a debilitating consequence of DM, with a prevalence ranging from 10 to 26% [1](#ner12908-bib-0001){ref-type="ref"}, [2](#ner12908-bib-0002){ref-type="ref"}, [3](#ner12908-bib-0003){ref-type="ref"}. PDPN typically presents as burning, electric, stabbing, or tingling neuropathic pain that starts in the lower limbs, and is characterized by diffuse damage to small nerve fibers, specifically to those of the Aδ and C type [4](#ner12908-bib-0004){ref-type="ref"}. Numerous pharmacological drugs for neuropathic pain have been introduced over the years [5](#ner12908-bib-0005){ref-type="ref"}. As the efficacy of pharmacological drugs in PDPN is limited, there is an urgent need for the development of novel treatment options.

Spinal cord stimulation of the dorsal columns (SCS) is a recommended last resort therapy for PDPN patients who do not respond to conventional pharmacological medication. The effectiveness of SCS in PDPN has been demonstrated in two randomized clinical trials (RCTs) [6](#ner12908-bib-0006){ref-type="ref"}, [7](#ner12908-bib-0007){ref-type="ref"}, [8](#ner12908-bib-0008){ref-type="ref"}. Despite considerable improvements, there are limitations to the efficacy of SCS. First, approximately 60% of patients with PDPN achieve pain reductions of ≥50% [6](#ner12908-bib-0006){ref-type="ref"}, [7](#ner12908-bib-0007){ref-type="ref"}, [8](#ner12908-bib-0008){ref-type="ref"}. Second, SCS is often unable to satisfactorily and specifically stimulate difficult‐to‐reach areas, such as the extremities in PDPN. Third, placement of the leads on top of the dorsal columns makes SCS with conventional settings susceptible to postural variations due to changes in distance between stimulation lead and stimulation target, leading to unpleasant paresthesias and/or overstimulation [9](#ner12908-bib-0009){ref-type="ref"}. Last, the energy consumption of SCS is relatively high, as there is significant energy loss to surroundings, such as the cerebrospinal fluid, before stimulation reaches the spinal cord dorsal columns.

In the field of neuromodulation, new developments aimed to change not only the anatomical target but also to introduce new stimulation waveforms have been suggested to overcome most of the disadvantages of SCS. Change of anatomical target from the spinal cord to the dorsal root ganglion (dorsal root ganglion stimulation, DRGS) not only increased treatment success in chronic intractable neuropathic pain but also resulted in less postural variation in paresthesia intensity and less battery consumption as compared to SCS [10](#ner12908-bib-0010){ref-type="ref"}. Additionally, DRGS was found to be a safe and effective neuromodulation modality that improves painful symptoms in PDPN patients [11](#ner12908-bib-0011){ref-type="ref"}. The introduction of new stimulation waveforms including use of burst paradigms [12](#ner12908-bib-0012){ref-type="ref"} have been shown to result in clinically relevant pain reductions, without eliciting paresthesias. Studies have shown that burst SCS (Burst‐SCS) decreases pain intensity to a greater degree than conventional SCS (Con‐SCS) [13](#ner12908-bib-0013){ref-type="ref"}, [14](#ner12908-bib-0014){ref-type="ref"}. This superior effect might be attributed to the underlying mechanism of action of Burst‐SCS, as it is hypothesized that Burst‐SCS, besides targeting brain areas related to the location and intensity of pain (lateral pain pathway), also targets areas related to the emotional and affective components of pain (medial pain pathway) [13](#ner12908-bib-0013){ref-type="ref"}.

Over the years, preclinical research has provided valuable information with regard to the therapeutic effects of neuromodulation for PDPN. The effectiveness of SCS in experimental PDPN has been demonstrated in both the short [15](#ner12908-bib-0015){ref-type="ref"}, [16](#ner12908-bib-0016){ref-type="ref"} and long term [17](#ner12908-bib-0017){ref-type="ref"}. Interestingly, the first *in vivo* study to test the effectiveness of DRGS in an animal model of peripheral nerve injury was recently published [18](#ner12908-bib-0018){ref-type="ref"}. The authors showed that DRGS attenuated both reflex‐based pain behavior as well as affective pain behavior, with no signs of histological damage to the DRG.

In line with the recent changes in the field of neuromodulation, a combination of novel anatomical targeting and the use of novel stimulation waveforms might provide a platform to further improve neuromodulatory therapies for chronic neuropathic pain. To date, no study has explored the effect of novel DRGS modalities, like Burst‐DRGS, in experimental or clinical PDPN. The present study, therefore, aimed to assess the effect of Burst‐DRGS vs. Con‐DRGS in an animal model of PDPN. To this end, we used an animal model for DRGS, which was demonstrated to relieve neuropathic pain in rats [18](#ner12908-bib-0018){ref-type="ref"}. Based on the aforementioned evidence on Burst stimulation in the field of SCS, we hypothesized that Burst‐DRGS leads to significantly higher pain relief and higher responder rates compared to Con‐DRGS.

METHODS {#ner12908-sec-0009}
=======

Ethical Statement {#ner12908-sec-0010}
-----------------

All experiments were conducted in a humane manner in accordance with the European Directive for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (86/609/EU). The study was approved by the Animal Research Committee of Maastricht University (DEC‐protocol 2013‐079).

Animals {#ner12908-sec-0011}
-------

All experiments were performed using young‐adult, female Sprague--Dawley rats (6 weeks at study onset, 180--220 g, *n* = 48). Animals were housed per 2 in filter‐top polycarbonate cages in a climate controlled room (temperature 21 ± 1°C, humidity 55 ± 15%) with constant background music (approximately 45 decibel) and under artificial lightning (12:12 reversed light/dark cycle). Distilled water and food was at all times available to the animals *ad libitum*. Animals were allowed to acclimatize to the housing facility without experimenter contact for 1 week after arrival, and were handled properly before the onset of the experiments.

Induction of Diabetes Mellitus {#ner12908-sec-0012}
------------------------------

DM was induced by a single intraperitoneal injection of 65 mg/kg Streptozotocin (STZ; Sigma‐Aldrich, Schnelldorf, Germany; *n* = 48). Prior to STZ injection, animals were weighed and fasted overnight. STZ was then freshly dissolved in sterile 0.9% NaCl to a solution of 65 mg/mL. In the first week after STZ injection, blood glucose levels were assessed in blood derived from the saphenous vein using a blood glucose meter (Accu‐Chek Aviva®, Roche Diagnostics GmbH, Mannheim, Germany). Rats with a glucose level of ≥15 mmol/L were considered diabetic [19](#ner12908-bib-0019){ref-type="ref"} and were included in the study. When glucose levels exceeded 31.4 mmol/L, one‐third of a slow releasing insulin pellet (LinShin Canada, Inc.) was placed subcutaneously in the trunk of the animal.

Assessment of Mechanical Hypersensitivity (Von Frey Assay) {#ner12908-sec-0013}
----------------------------------------------------------

Mechanical hypersensitivity was assessed by measuring the response of the hind paws to Von Frey filaments using the "up‐down" method [20](#ner12908-bib-0020){ref-type="ref"}. In short, rats were placed in a transparent box on an elevated mesh floor. Animals were allowed to acclimate to the behavioral set‐up for 15 min before testing. Subsequently, a series of Von Frey filaments with incrementing stiffness (bending forces 0.6, 1.2, 2.0, 3.6, 5.5, 8.5, 15.1, and 28.84 g) were applied to the plantar surface of the hind paws of the animals for 5 sec. In case of a negative response (no withdrawal of hind paw), the next filament with higher bending force was applied. In case of a positive response (withdrawal of hind paw), the previous filament with lower bending force was applied. The 50% withdrawal threshold (WT) was calculated after completion of a sequence of six consecutive responses. A cut‐off value of 28.84 g was defined to prevent tissue damage. Last, the 50% WT was multiplied by 10,000 and logarithmically transformed to account for Weber\'s law [21](#ner12908-bib-0021){ref-type="ref"} and obtain a linear scale.

Development of Mechanical Hypersensitivity {#ner12908-sec-0014}
------------------------------------------

Only animals showing mechanical hypersensitivity on the Von Frey assay at 4 weeks after STZ injection were implanted and treated with DRGS. Animals without mechanical hypersensitivity were excluded from the study. The presence of mechanical hypersensitivity was defined as a decrease of ≥0.2 unit in log~10~ (10,000 x 50% WT) when compared to pre‐STZ values [15](#ner12908-bib-0015){ref-type="ref"}, [16](#ner12908-bib-0016){ref-type="ref"}, [17](#ner12908-bib-0017){ref-type="ref"}.

Dorsal Root Ganglion Stimulation Lead {#ner12908-sec-0015}
-------------------------------------

Preparation of the DRGS lead was performed as previously described [18](#ner12908-bib-0018){ref-type="ref"}. Briefly, the lead was manufactured out of two platinum--iridium wires with different diameters (0.010 and 0.005 in). The insulation at the termini of both wires was removed, and the terminal of the large wire (0.010 in) was bent back upon itself to produce an atraumatic tip. The smaller wire (0.005 in) was then wrapped around the insulated part of the larger wire. A few spots of dental cement were added to strengthen the lead. Last, the lead was tested with an Ohmmeter to confirm proper functioning of the lead (Fig. [1](#ner12908-fig-0001){ref-type="fig"}).

![Bipolar DRGS lead.](NER-22-943-g001){#ner12908-fig-0001}

Implantation of the DRGS Lead {#ner12908-sec-0016}
-----------------------------

Implantation of the DRGS lead at the L5 DRG was performed as previously described [18](#ner12908-bib-0018){ref-type="ref"}. Briefly, the intervertebral foramen at the level of the fifth lumbar (L5) spinal nerve was exposed via a paravertebral incision under general anesthesia. Subsequently, the foramen was gently opened by probing with a small, blunt nerve hook to provide a passage for the lead to enter the foramen on the dorsolateral aspect of the L5 DRG. The lead was secured onto the transverse process caudal to the foramen using a stainless steel ligature and a small screw (diameter 0.86 mm, length 3.2 mm). This produced a device capable of providing bipolar contact in apposition to the L5 DRG. Last, the lead was tunneled subcutaneously through the neck of the animals and the wounds were closed in layers. After implantation of the lead, the rats were allowed to recover for 2 days before the start of DRGS.

DRG Stimulation {#ner12908-sec-0017}
---------------

For stimulation of the L5 DRG, an A‐M systems stimulator (MultiStim: Programmable 8‐Channel Stimulator (Model 3800) 220 V/50 Hz) fitted with an additional stimulus Isolator (Model 3820 for A‐M Systems MultiStim) was used. After connecting the implanted lead to the stimulator, the motor threshold (MT) was determined using a frequency of 2 Hz and pulse width of 200 μsec for Con‐DRGS, and a pulse width of 1000 μsec, five pulses (500 Hz intraburst frequency) administered at an interburst frequency of 2 Hz for Burst‐DRGS. MT was defined as the current inducing contractions of the lower trunk or hind limb(s). For Con‐DRGS, the stimulation settings were as follows: biphasic stimulation with frequency = 50 Hz, pulse width = 200 μsec, amplitude = 67% of motor threshold (Fig. [2](#ner12908-fig-0002){ref-type="fig"}a). For Burst‐DRGS, the stimulation settings were as follows: monophasic stimulation with interburst frequency = 40 Hz, intraburst frequency = 500 Hz, pulse width = 1000 μsec, interpulse interval = 1000 μsec, burst pulse count = 5, amplitude = 67% MT [12](#ner12908-bib-0012){ref-type="ref"}, [13](#ner12908-bib-0013){ref-type="ref"}, [14](#ner12908-bib-0014){ref-type="ref"} (Fig. [2](#ner12908-fig-0002){ref-type="fig"}b). Animals with an MT of ≥1 mA at stimulation days were excluded from analysis. For sham stimulated animals, the amplitude was set at zero. Animals were unrestrained during DRGS.

![Oscilloscope output of the Con‐DRGS (a) and Burst‐DRGS (b) waveform. Con‐DRGS: biphasic mode with frequency = 50 Hz, pulse width = 200 μsec. Burst‐DRGS: monophasic mode with interburst frequency = 40 Hz, intraburst frequency = 500 Hz, pulse width = 1000 μsec, interpulse interval = 1000 μsec, burst pulse count = 5.](NER-22-943-g002){#ner12908-fig-0002}

Timeline of Experiments {#ner12908-sec-0018}
-----------------------

Following baseline measurements for mechanical hypersensitivity (Von Frey; week −1), animals were injected with STZ (week 0). In the first week after STZ injection (week 1), blood glucose of the animals was measured to confirm DM (DM defined as blood glucose level ≥15 mmol/L [19](#ner12908-bib-0019){ref-type="ref"}). Four weeks after STZ injection (week 4), animals were again tested for mechanical hypersensitivity, to select animals that developed PDPN (≥0.2 decrease in log~10~ (10,000 x 50% WT) on Von Frey when compared to the pre‐STZ baseline [15](#ner12908-bib-0015){ref-type="ref"}, [16](#ner12908-bib-0016){ref-type="ref"}, [17](#ner12908-bib-0017){ref-type="ref"}) for DRGS implantation (week 5). PDPN animals received either Con‐DRGS and Burst‐DRGS in a randomized cross‐over design on days 2 and 3 postimplantation, or were assigned to a Sham‐DRGS group (50% WT measured on day 2). The experimenter was blinded for the DRGS paradigm used. On stimulation days, animals were first tested for MT, after which the amplitude was set accordingly. Animals were then tested for mechanical hypersensitivity on Von Frey just before DRGS onset (baseline), 15 and 30 min during DRGS (or sham‐DRGS), and 15 and 30 min after DRGS (45 and 60 min; Fig. [3](#ner12908-fig-0003){ref-type="fig"}).

![Timeline of experiments.](NER-22-943-g003){#ner12908-fig-0003}

Statistical Analysis {#ner12908-sec-0019}
--------------------

The WTs to Von Frey filaments are presented as mean ± standard error of the mean. For statistical analysis, Von Frey data were logarithmically transformed to account for Weber\'s Law [21](#ner12908-bib-0021){ref-type="ref"} and obtain a linear scale. Data were tested for a normal distribution using the Shapiro--Wilk normality test and were confirmed to be normally distributed. For analysis of intragroup changes in WTs over time, one‐way repeated measures analysis of variance (ANOVA) was performed, followed by Tukey\'s multiple comparison test. For between‐groups analysis (Con‐DRGS vs. Burst‐DRGS vs. Sham‐DRGS), a two‐way ANOVA followed by Tukey\'s multiple comparisons test was used. For comparisons between pre‐STZ WTs and preimplant WTs, and comparisons of MTs between the Con‐DRGS and Burst‐DRGS group, a paired‐samples *t*‐test was used.

RESULTS {#ner12908-sec-0020}
=======

Flowchart of Animals {#ner12908-sec-0021}
--------------------

Out of the 48 animals that were injected with STZ, 43 developed DM (90%; blood glucose level ≥15 mmol/L). One animal died as a result from STZ‐related health deterioration. Thirteen animals required insulin treatment (blood glucose level ≥31.4 mmol/L). Twenty‐five out of the 43 diabetic animals developed subsequent PDPN 4 weeks post‐STZ injection (58%; ≥0.2 decrease in log~10~ (10,000 x 50% WT) on Von Frey when compared to the pre‐STZ baseline [15](#ner12908-bib-0015){ref-type="ref"}, [16](#ner12908-bib-0016){ref-type="ref"}, [17](#ner12908-bib-0017){ref-type="ref"}), of which 22 were successfully implanted with a DRGS device. Two out of the 22 implanted PDPN animals were withdrawn from the study due to connector breakage before the first stimulation day, one animal was withdrawn from the study due to not being able to finish the complete study period (no motor threshold observed on second stimulation day), and two animals were excluded from the study because of high MT (MT ≥1 mA). Consequently, 17 animals were left for analysis. Of these 17 animals, 10 animals received Con‐DRGS and Burst‐DRGS in a randomized cross‐over design, and 7 animals received Sham‐DRGS.

Development of STZ‐Induced Mechanical Hypersensitivity {#ner12908-sec-0022}
------------------------------------------------------

The mean log~10~ (10,000 x 50% WT) value of the 17 stimulated animals (animals that underwent Con‐DRGS, Burst‐DRGS, or Sham‐DRGS) dropped from 5.06 ± 0.04 before STZ injection to 4.47 ± 0.04 preimplantation (4 weeks following STZ injection; *p* \< 0.0001; Fig. [4](#ner12908-fig-0004){ref-type="fig"}).

![Development of mechanical hypersensitivity after STZ injection of all stimulated rats (animals that underwent Con‐DRGS, Burst‐DRGS, or Sham‐DRGS; *n* = 17). \*\*\*\* *p* \< 0.0001 compared to pre‐STZ baseline.](NER-22-943-g004){#ner12908-fig-0004}

Effect of Con‐DRGS on STZ‐Induced Mechanical Hypersensitivity {#ner12908-sec-0023}
-------------------------------------------------------------

For animals receiving Con‐DRGS, the average baseline log~10~ (10,000 x 50% WT) score (before start of Con‐DRGS) was 4.38 ± 0.07. Con‐DRGS resulted in a significant reduction of mechanical hypersensitivity at 15 min (4.81 ± 0.12, *p* \< 0.05) and 30 min (5.01 ± 0.12, *p* \< 0.01), when compared to baseline. Log~10~ (10,000 x 50% WT) scores returned to baseline values after cessation of Con‐DRGS at 45 min (4.41 ± 0.06, *p* \> 0.99) and 60 min (4.42 ± 0.08, *p* \> 0.99). No residual effect was observed for Con‐DRGS, as both the 45 and 60 min time point were significantly different compared to the 30 min time point (*p* \< 0.01), while no significant difference was observed between the 45 and 60 min time points and baseline (*p* \> 0.99; Fig. [5](#ner12908-fig-0005){ref-type="fig"}a).

![Scatter plot of the effect of Con‐DRGS (*n* = 10) (a), Burst‐DRGS (*n* = 10) (b), and Sham‐DRGS (*n* = 7) (c) on STZ‐induced mechanical hypersensitivity. A combined presentation of the effect of Con‐DRGS, Burst‐DRGS, and Sham‐DRGS is presented in (d). Dotted line = the mean pre‐STZ baseline of all stimulated animals. Gray area = period of DRGS. \*, \*\**p* \< 0.05, *p* \< 0.01 compared to prestimulation baseline; \$, \$\$, \$\$\$*p* \< 0.05, *p* \< 0.01, *p* \< 0.001 compared to *T* = 30 min; \#, \#\#, \#\#\#*p* \< 0.05, *p* \< 0.01, *p* \< 0.001 compared to the Sham‐DRGS group at the same time point.](NER-22-943-g005){#ner12908-fig-0005}

Effect of Burst‐DRGS on STZ‐Induced Mechanical Hypersensitivity {#ner12908-sec-0024}
---------------------------------------------------------------

For animals receiving Burst‐DRGS, the average baseline log~10~ (10,000 x 50% WT) score (before start of Burst‐DRGS) was 4.31 ± 0.06. Burst‐DRGS resulted in a significant reduction of mechanical hypersensitivity at 15 min (4.91 ± 0.13, *p* = 0.01) and 30 min (4.90 ± 0.16, *p* = 0.02), when compared to baseline. Log~10~ (10,000 x 50% WT) scores returned to baseline values after cessation of Burst‐DRGS at 45 min (4.58 ± 0.15, *p* = 0.40) and 60 min (4.52 ± 0.10, *p* = 0.15). Importantly, Burst‐DRGS showed signs of a residual effect at 45 min (15 min after stimulation), as there was no significant difference in the efficacy of Burst‐DRGS at the 45 min time point when compared to the 30 min time point (*p* \> 0.05) and baseline (*p* = 0.40; Fig. [5](#ner12908-fig-0005){ref-type="fig"}b).

Effect of Sham‐DRGS on STZ‐Induced Mechanical Hypersensitivity {#ner12908-sec-0025}
--------------------------------------------------------------

For animals receiving Sham‐DRGS, the average baseline log~10~ (10,000 x 50% WT) score (before start of Sham‐DRGS) was 4.42 ± 0.04. No significant differences in mechanical hypersensitivity were found at 15 min (4.35 ± 0.08, *p* = 0.88), 30 min (4.38 ± 0.13, *p* \> 0.99), 45 min (4.35 ± 0.10, *p* = 0.90), and 60 min (4.38 ± 0.12, *p* \> 0.99), when compared to baseline. Furthermore, no significant difference was observed between any of the tested time points (*p* \> 0.88; Fig. [5](#ner12908-fig-0005){ref-type="fig"}c).

Effect of Con‐DRGS vs. Burst‐DRGS vs. Sham‐DRGS on STZ‐Induced Mechanical Hypersensitivity {#ner12908-sec-0026}
------------------------------------------------------------------------------------------

A significant difference between Con‐DRGS and Sham‐DRGS log~10~ (10,000 x 50% WT) values was observed at 15 min of stimulation (4.81 ± 0.12 vs. 4.35 ± 0.08, *p* = 0.02) and 30 min of stimulation (5.01 ± 0.12 vs. 4.38 ± 0.13, *p* \< 0.001). No significant differences in terms of log~10~ (10,000 x 50% WT) values were observed between Con‐DRGS and Sham‐DRGS at baseline (4.38 ± 0.07 vs. 4.42 ± 0.04, *p* = 0.98), 45 min (4.41 ± 0.06 vs. 4.35 ± 0.10, *p* = 0.92), and 60 min (4.42 ± 0.08 vs. 4.38 ± 0.12, *p* = 0.97).

A significant difference was also observed between Burst‐DRGS and Sham‐DRGS log~10~ (10,000 x 50% WT) values at 15 min of stimulation (4.91 ± 0.13 vs. 4.35 ± 0.08, *p* \< 0.01) and 30 min of stimulation (4.90 ± 0.16 vs. 4.38 ± 0.13, *p* \< 0.01). No significant differences in terms of log~10~ (10,000 x 50% WT) values were observed between Burst‐DRGS and Sham‐DRGS at baseline (4.31 ± 0.06 vs. 4.42 ± 0.04, *p* = 0.81), 45 min (4.58 ± 0.15 vs. 4.35 ± 0.10, *p* = 0.32), and 60 min (4.52 ± 0.10 vs. 4.38 ± 0.12, *p* = 0.68).

No significant differences were observed between Con‐DRGS and Burst‐DRGS at any time point: Baseline: 4.38 ± 0.07 vs. 4.31 ± 0.06, *p* = 0.88; 15 min: 4.81 ± 0.12 vs. 4.91 ± 0.13, *p* = 0.80; 30 min: 5.01 ± 0.12 vs. 4.90 ± 0.16, *p* = 0.55; 45 min: 4.41 ± 0.06 vs. 4.58 ± 0.15, *p* = 0.48; 60 min: 4.42 ± 0.08 vs. 4.52 ± 0.10, *p* = 0.78 (Fig. [5](#ner12908-fig-0005){ref-type="fig"}d). Additionally, observed MTs were lower in the Burst‐DRGS group compared to the Con‐DRGS group, albeit not significant (*p* = 0.12; Fig. [6](#ner12908-fig-0006){ref-type="fig"}).

![Motor thresholds (MT) assessed by means of Con‐DRGS and Burst‐DRGS. The MT of Con‐DRGS was assessed at 2 Hz and pulse width of 200 μsec. The MT of Burst‐DRGS was assessed using a pulse width of 1000 μsec, and five pulses (500 Hz intraburst frequency) administered at an interburst frequency of 2 Hz.](NER-22-943-g006){#ner12908-fig-0006}

Percentage Responders: Con‐DRGS vs. Burst‐DRGS {#ner12908-sec-0027}
----------------------------------------------

The percentage of responders to Con‐DRGS was 70% (seven out of ten) at 15 min, 90% (nine out of ten) at 30 min of stimulation, 20% (two out of ten) at 45 min, and 33% (three out of ten) at 60 min. In the Burst‐DRGS group, the percentage of responders was 80% (eight out of ten) at 15 min, 70% (seven out of ten) at 30 min of stimulation, 50% (five out of ten) at 45 min, and 40% (four out of ten) at 60 min. A responder was defined as an animal with an increase of ≥0.2 unit in log~10~ (10,000 x 50% WT) at the 15, 30, 45, or 60 min marks when compared to baseline before stimulation onset (Table [1](#ner12908-tbl-0001){ref-type="table"}).

###### 

Percentage Responders to Con‐DRGS and Burst‐DRGS at 15, 30, 45, and 60 min.

  Group        *T* = 15 min   *T* = 30 min   *T* = 45 min   *T* = 60 min
  ------------ -------------- -------------- -------------- --------------
  Con‐DRGS     7/10 (70%)     9/10 (90%)     2/10 (20%)     3/10 (33%)
  Burst‐DRGS   8/10 (80%)     7/10 (70%)     5/10 (50%)     4/10 (40%)

A responder to stimulation was defined as an animal with an increase of the 10log (10,000 x 50%WT) ≥0.2 during stimulation compared to the prestimulation baseline.

DISCUSSION {#ner12908-sec-0028}
==========

This is the first study to compare Burst‐DRGS with Con‐DRGS in PDPN. Our findings showed that both Con‐DRGS and Burst‐DRGS are equally effective in reversing STZ‐induced mechanical hypersensitivity to pre‐STZ baseline values. Since Con‐DRGS was already very effective in bringing log~10~ (10,000 x 50% WT) values back to the healthy baseline level after 30 min of stimulation, it might have been challenging to show statistically significant improvements with Burst‐DRGS over this effective Con‐DRGS therapy. Nevertheless, Burst‐DRGS showed signs of a residual effect (not significant) at 15 min after cessation of stimulation, while this was not the case for Con‐DRGS‐treated animals. Also the responder rates were considerably higher in the Burst‐DRGS (5/10; 50%) group when compared to the Con‐DRGS group (2/10; 20%) 15 min after cessation of stimulation. Our results are in line with the work of Pan et al., who were the first to perform *in vivo* Con‐DRGS in a unilateral peripheral nerve injury model of neuropathic pain [18](#ner12908-bib-0018){ref-type="ref"}. The authors concluded that Con‐DRGS attenuates both reflex‐based as well as affective pain behavior. Also the observed motor thresholds in the study of Pan et al. [18](#ner12908-bib-0018){ref-type="ref"} were comparable to those observed in our study. Importantly, the study of Pan and colleagues also showed that DRGS produces no signs of histological or behavioral injury to the DRG.

Also clinically, the effectiveness of Con‐DRGS and the superiority of Con‐DRGS over Con‐SCS for the treatment of chronic intractable pain of the lower limbs attributed to complex regional pain syndrome and causalgia has been published in a RCT [10](#ner12908-bib-0010){ref-type="ref"}. Additionally, the first retrospective study to assess the effect of Con‐DRGS for refractory PDPN patients was recently published by Eldabe et al. [11](#ner12908-bib-0011){ref-type="ref"}. Despite the retrospective nature and small sample size (ten patients) of this study, the authors concluded that Con‐DRGS is a safe and effective neuromodulation modality to improve painful symptoms in PDPN patients [11](#ner12908-bib-0011){ref-type="ref"}.

In the field of Burst stimulation, contradictory findings regarding the superiority of Burst‐SCS over Con‐SCS have been reported. While some studies show a clear advantage of Burst‐SCS over Con‐SCS [13](#ner12908-bib-0013){ref-type="ref"}, [14](#ner12908-bib-0014){ref-type="ref"}, [22](#ner12908-bib-0022){ref-type="ref"}, other studies show no difference between the two stimulation modalities in terms of their pain relieving effect [23](#ner12908-bib-0023){ref-type="ref"}, which may have resulted from the different disease indications assessed in these studies. The superiority of Burst‐SCS observed in some studies might be attributed to the mechanism of action of Burst‐SCS, as it is hypothesized that Burst‐SCS, besides targeting brain areas related to the location and intensity of pain (lateral pain pathway), also target areas related to the emotional and affective components of pain (medial pain pathway) [13](#ner12908-bib-0013){ref-type="ref"}. Furthermore, a study by Tang et al. found that Burst‐SCS at 60% MT reduced neural activity significantly more than Con‐SCS at the same amplitude, which might explain the superiority of Burst‐SCS over Con‐SCS [24](#ner12908-bib-0024){ref-type="ref"}. Last, the total charge per second is higher with Burst‐SCS when compared to Con‐SCS, something that is hypothesized to correlate with stimulation efficacy [25](#ner12908-bib-0025){ref-type="ref"}. In our study, no significant difference was found between Con‐DRGS and Burst‐DRGS on STZ‐induced mechanical hypersensitivity. Nevertheless, the inclusion of only reflex‐based tests in the present study might limit our window for detecting differences related to motivational affective aspects of pain [13](#ner12908-bib-0013){ref-type="ref"}. Also, the Burst waveform used in the present study, albeit monophasic, varies slightly from the clinically‐used BurstDR waveform, which is monophasic with a passive recharge balance.

The present preclinical DRGS model mimics features that are typical of clinical DRGS. As is the case in clinical DRGS, pain relief occurred very promptly (after 15 min of stimulation) in our animal model for both Con‐DRGS and Burst‐DRGS, and was maintained for the full 30 min stimulation period. Interestingly, a recent study by Meuwissen et al., which compared Con‐SCS with Burst‐SCS in an animal model of peripheral nerve injury, showed Burst‐SCS to have a delayed onset and a delayed carry‐over of analgesic effect when compared to Con‐SCS [26](#ner12908-bib-0026){ref-type="ref"}. While no differences in terms of a delayed onset of analgesic effect was observed between Con‐DRGS and Burst‐DRGS in the present study, Burst‐DRGS appeared to show signs of a residual effect at 45 min when compared to Con‐DRGS. Differences in the delayed wash‐in of stimulation might be attributed to differences in the experimental model used, the location of stimulation (dorsal column vs. DRG), the type of stimulation (quadripolar vs. bipolar), and/or the Burst paradigm used (biphasic vs. monophasic). The motor thresholds necessary to evoke contractions of the hind paws of the animals were lower for Burst‐DRGS than Con‐DRGS in our study, albeit not significant. This is in line with preclinical findings that Burst‐SCS requires significantly lower amplitudes to obtain a motor response when compared to Con‐SCS [24](#ner12908-bib-0024){ref-type="ref"}, [26](#ner12908-bib-0026){ref-type="ref"}, [27](#ner12908-bib-0027){ref-type="ref"}, [28](#ner12908-bib-0028){ref-type="ref"}, [29](#ner12908-bib-0029){ref-type="ref"}, [30](#ner12908-bib-0030){ref-type="ref"}. The latter has important consequences for the stimulation amplitude, which is generally lower with Burst‐SCS when compared to Con‐SCS [12](#ner12908-bib-0012){ref-type="ref"}.

To date, few studies have been conducted to elucidate the mechanism underlying DRGS. DRGS was found to inhibit neuronal excitability, by reducing the amplitude and/or the amount of action potentials arising from the DRG [31](#ner12908-bib-0031){ref-type="ref"}. The unique pseudo‐unipolar design and the T‐junction of the DRG may act as a low‐pass filter for electrical stimuli traveling from the periphery to the spinal cord [32](#ner12908-bib-0032){ref-type="ref"}. Furthermore, it was shown by fMRI that DRGS is capable of attenuating BOLD signals in brain regions that are considered part of the pain matrix, like the contralateral thalamic VPL/VPM nuclei, and cortical S1 and S2 [33](#ner12908-bib-0033){ref-type="ref"}. However, the involvement of the spinal pain gate should not be overlooked, as modulating firing rates of DRG neurons by DRGS may also affect interneurons and GABAergic systems in the dorsal horn as is the case in traditional SCS [34](#ner12908-bib-0034){ref-type="ref"}, [35](#ner12908-bib-0035){ref-type="ref"}, [36](#ner12908-bib-0036){ref-type="ref"}. Interestingly, it was shown that Burst‐SCS does not rely on GABAergic mechanisms as is the case for Con‐SCS, as it was shown that the effect of Con‐SCS, but not Burst‐SCS, is blocked by administration of a GABA‐B receptor antagonist [28](#ner12908-bib-0028){ref-type="ref"}, suggesting that different mechanisms of action underlie different stimulation waveforms. Recently, a study by Du et al. found an extensive GABAergic communication network between sensory neuron somata inside the DRG [37](#ner12908-bib-0037){ref-type="ref"}. The authors showed that sensory neurons in the DRG express major proteins required for GABA synthesis and release, and are capable of releasing GABA upon depolarization. Furthermore, it was found that local infusion of GABA reuptake inhibitors into the DRG alleviated neuropathic pain, whereas focal application of GABA receptor antagonists triggered neuropathic pain. The authors proposed the idea that this GABAergic system in the DRG acts as a second gate, in addition to the Gate Control Theory [38](#ner12908-bib-0038){ref-type="ref"}, and that neuromodulation of the DRG might exert its analgesic action by engaging this second gate [37](#ner12908-bib-0037){ref-type="ref"}. More research into the underlying mechanisms of DRGS and its relation to specific stimulation waveforms is necessary to fine‐tune DRGS for chronic neuropathic pain diseases.

Limitations of this study include the use of only a short‐term stimulation protocol. Long‐term stimulation protocols, as being used in clinical practice, require further investigation. Second, only female Sprague--Dawley rats were included in our study as female Sprague--Dawley rats reach their maximal body weight and nerve conduction values faster and at a lower weight when compared to male Sprague--Dawley rats or either sex of other strains [19](#ner12908-bib-0019){ref-type="ref"}. As there is strong evidence for sex differences in pain and analgesia, one should be cautious when extrapolating these data to the male sex [39](#ner12908-bib-0039){ref-type="ref"}. As mentioned earlier, also the inclusion of only reflex‐based tests has its limitations and the Burst waveform used in the present study varies slightly from the clinically used BurstDR waveform.

We conclude that under the conditions tested, Con‐DRGS and Burst‐DRGS are equally effective in attenuating streptozotocin‐induced mechanical hypersensitivity in an animal model of PDPN. Importantly, Burst‐DRGS showed signs of a residual effect at 15 min after cessation of stimulation, which was not the case with Con‐DRGS. Further work needs to be done to confirm this residual effect of Burst‐DRGS. The present study provides a first insight into the pain relieving effect of Burst‐DRGS. Further optimization and analysis of DRGS driven by insights into the underlying mechanisms of the various stimulation paradigms is necessary.
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The importance of painful diabetic peripheral neuropathy as a potential application for neuromodulation cannot be overstated. The commonness of this condition means that it has the potential to become the biggest single indication for stimulation. It is therefore critical that we develop a robust evidence base for treatment, incorporating laboratory studies such as this as well as clinical trials.

James Fitzgerald, MA, BM BCh, PhD

*Oxford, UK*

Comments not included in the Early View version of this paper.
